LNSR Lensar (LNSR) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001320350
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
36
13F, latest reported quarter
Lensar insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for LENSAR, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 22 earlier Form 4 trades (code P or S) here by this insider (22 buys), the last on Aug 28, 2024.
- +61.8% median (+39.7% mean) 90-day return after 21 previous buys.
- The trade is 0.8% of the 80,840 shares held after it.
- No other insider bought within 30 days.
- 36 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Winer Gary M bought about $3.1K of LNSR on Sep 3, 2024; 36 funds added in the latest 13F quarter.Context
- 21 earlier Form 4 trades (code P or S) here by this insider (21 buys), the last on Aug 27, 2024.
- +63.3% median (+38.7% mean) 90-day return after 20 previous buys.
- The trade is 1.2% of the 80,155 shares held after it.
- No other insider bought within 30 days.
- 36 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Winer Gary M bought about $4.5K of LNSR on Aug 28, 2024, the largest insider purchase at the company since 2023; 36 funds added in the latest 13F quarter.Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 buys), the last on Aug 26, 2024.
- +64.8% median (+37.7% mean) 90-day return after 19 previous buys.
- The trade is 0.6% of the 79,155 shares held after it.
- No other insider bought within 30 days.
- 36 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Winer Gary M bought about $2.2K of LNSR on Aug 27, 2024; 36 funds added in the latest 13F quarter.Context
- 19 earlier Form 4 trades (code P or S) here by this insider (19 buys), the last on Aug 22, 2024.
- +65.1% median (+36.4% mean) 90-day return after 18 previous buys.
- The trade is 1.0% of the 78,655 shares held after it.
- No other insider bought within 30 days.
- 36 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Winer Gary M bought about $3.7K of LNSR on Aug 26, 2024; 36 funds added in the latest 13F quarter.Context
- 18 earlier Form 4 trades (code P or S) here by this insider (18 buys), the last on Aug 21, 2024.
- +64.8% median (+34.7% mean) 90-day return after 17 previous buys.
- The trade is 0.0% of the 77,853 shares held after it.
- No other insider bought within 30 days.
- 36 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Winer Gary M bought about $9 of LNSR on Aug 22, 2024; 36 funds added in the latest 13F quarter.29 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
36 funds bought in last quarter
below 65% of Medical Devices
Revenue
+12.4% year over year
more than 55% of Medical Devices
Margin
-66.4% net margin
below 73% of Medical Devices
Buybacks
no share repurchases reported
Short interest
3.6% of the float short (float per yahoo 2026-10-26) · 6.6 days to cover · settled 2026-09-30
below 61% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch LNSR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-50.3%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LNSR: institutional holders (13F)
13F holdings, latest reported quarter
1,075,400 sh
$6.1M
402,806 sh
$2.3M
213,537 sh
$1.2M
188,661 sh
$1.1M
185,033 sh
$1.1M
Congress trades in LNSR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
LNSR planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
LNSR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Brandes Small Cap Value Fund
$3.0M position · as of 2026-06-30
0.5%
Enterprise Mergers and Acquisitions Fund
$137.0K position · as of 2026-06-30
0.2%
1290 VT GAMCO Mergers & Acquisitions Portfolio
$188.4K position · as of 2026-06-30
0.1%
The Gabelli ABC Fund
$114.2K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$185.7K position · as of 2026-06-30
0.0%
Invesco Russell 2000 Dynamic Multifactor ETF
$32.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.3M
$3.2M
$928.7K
+231%
n/a
2024
$1.6M
$3.0M
$916.4K
+155%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 36 funds added last quarter. Each figure is a federal filing, dated the day it went public.
LNSR financials
Revenue growth
+12.4%
XBRL, annual
Net margin
-66.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$60.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM LNSR
| FY Dec 2025 | $58.4M |
| FY Dec 2024 | $53.5M |
| FY Dec 2023 | $42.2M |
| FY Dec 2022 | $35.4M |
| FY Dec 2021 | $34.5M |
| Jun 2026 | $16.5M |
| Mar 2026 | $13.4M |
| Dec 2025 | $16.0M |
| Sep 2025 | $14.3M |
| Jun 2025 | $13.9M |
| Mar 2025 | $14.2M |
| Dec 2024 | $16.7M |
| Sep 2024 | $13.5M |
At each fiscal year end
Single quarter
Net margin, TTM
+57.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM LNSR
| FY Dec 2025 | -58.7% |
| FY Dec 2024 | -58.7% |
| FY Dec 2023 | -34.1% |
| FY Dec 2022 | -56.3% |
| FY Dec 2021 | -56.9% |
| Jun 2026 | +21.4% |
| Mar 2026 | +270.6% |
| Dec 2025 | -9.1% |
| Sep 2025 | -25.9% |
| Jun 2025 | -12.7% |
| Mar 2025 | -193.1% |
| Dec 2024 | -111.8% |
| Sep 2024 | -11.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$7.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM LNSR
| FY Dec 2025 | -$14.9M |
| FY Dec 2024 | -$2.4M |
| FY Dec 2023 | -$9.9M |
| FY Dec 2022 | -$15.0M |
| FY Dec 2021 | -$9.3M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $618.0K |
| Sep 2025 | -$3.5M |
| Jun 2025 | -$5.1M |
| Mar 2025 | -$6.9M |
| Dec 2024 | $3.7M |
| Sep 2024 | $3.1M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity LNSR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt LNSR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity LNSR
| FY Dec 2025 | n/a |
| FY Dec 2024 | -164.0% |
| FY Dec 2023 | -38.1% |
| FY Dec 2022 | -41.1% |
| FY Dec 2021 | -32.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -16,632% |
| Mar 2025 | -1,168% |
| Dec 2024 | -164.0% |
| Sep 2024 | -56.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+49.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets LNSR
| FY Dec 2025 | -49.8% |
| FY Dec 2024 | -46.2% |
| FY Dec 2023 | -22.9% |
| FY Dec 2022 | -32.6% |
| FY Dec 2021 | -26.9% |
| Jun 2026 | +49.6% |
| Mar 2026 | +42.2% |
| Dec 2025 | -49.8% |
| Sep 2025 | -77.9% |
| Jun 2025 | -74.8% |
| Mar 2025 | -81.4% |
| Dec 2024 | -46.2% |
| Sep 2024 | -25.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital LNSR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-18.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed LNSR
| FY Dec 2025 | -59.8% |
| FY Dec 2024 | -19.5% |
| FY Dec 2023 | -23.9% |
| FY Dec 2022 | -39.5% |
| FY Dec 2021 | -30.6% |
| Jun 2026 | -18.0% |
| Mar 2026 | -35.1% |
| Dec 2025 | -59.8% |
| Sep 2025 | -49.4% |
| Jun 2025 | -32.0% |
| Mar 2025 | -26.8% |
| Dec 2024 | -19.5% |
| Sep 2024 | -22.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing LNSR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value LNSR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-9.9%
TTM free cash flow over market value at close 2026-10-23
FCF yield LNSR
| FY Dec 2025 | -10.7% |
| FY Dec 2024 | -2.3% |
| FY Dec 2023 | -25.1% |
| FY Dec 2022 | -45.9% |
| FY Dec 2021 | -14.2% |
| Jun 2026 | -10.7% |
| Mar 2026 | -17.0% |
| Dec 2025 | -10.7% |
| Sep 2025 | -8.1% |
| Jun 2025 | -3.4% |
| Mar 2025 | -2.4% |
| Dec 2024 | -2.3% |
| Sep 2024 | -12.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing LNSR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $58.4M | $53.5M | $42.2M | $35.4M |
| Operating income | -$24.6M | -$10.7M | -$12.2M | -$20.2M |
| Net income | -$34.3M | -$31.4M | -$14.4M | -$19.9M |
| EPS (diluted) | -2.87 | -2.73 | -1.31 | -1.96 |
| Operating cash flow | -$14.8M | -$2.3M | -$9.7M | -$14.9M |
| Cash | $13.0M | $16.3M | $20.6M | $14.7M |
SEC XBRL, fiscal years, as known on 2026-10-27
LNSR Stock Sonar score 4/7 axes
Find similar shapesCompareLNSR ranks highest on profitability (73rd percentile) and risk and compliance (68th), and lowest on institutional and government (35th), among Medical Devices peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
